1. CD39/CD73/A2a Adenosine Metabolic Pathway: Targets for Moxibustion in Treating DSS-Induced Ulcerative Colitis.
- Author
-
Zhu, Yuanbing, Zhuang, Zhiqi, Wu, Qiaofeng, Lin, Sirui, Zhao, Na, Zhang, Qun, Xie, Lushuang, and Yu, Shuguang
- Subjects
- *
ULCERATIVE colitis , *CYTOKINES , *INTERLEUKINS , *FLOW cytometry , *KRUSKAL-Wallis Test , *MOXIBUSTION , *ANALYSIS of variance , *ANIMAL experimentation , *WESTERN immunoblotting , *ONE-way analysis of variance , *CELL receptors , *HYDROLASES , *TREATMENT effectiveness , *TUMOR necrosis factors , *T cells , *ADENOSINES , *DATA analysis software , *DEXTRAN , *MICE - Abstract
Ulcerative Colitis (UC) is a chronic inflammation disease, and the incidence of UC is increasing recently. Both clinical trials and animal experiments show that moxibustion is a complementary and alternative treatment for UC. Previous studies showed that moxibustion can improve UC by regulating the balance of Tregs and Th17 (Sun et al., 2017). Treg cells is one subset of CD4 + T cells that exert the immunosuppressive function. CD39 and CD73, expressed on the surface of Tregs, hydrolyze ATP to AMP and are further involved in the immunosuppressive function of Tregs. In this study, we investigated the effect of moxibustion on CD39 + Tregs and CD73 + Tregs in dextran sulfate sodium (DSS) induced UC mice. The A2a receptor (A2aR), one of the targets of adenosine, was also detected. The results showed that moxibustion could increase the expression of CD39, CD73, and A2aR in colonic tissue and improve the proportion of CD39 + Tregs and CD73 + Tregs in peripheral blood, inguinal draining lymph nodes and spleen in the UC model. Additionally, A2aR agonists enhanced the cell viability of colonic epithelial cells and inhibit the production of cytokines IL-6 and TNF- α in vitro, which may further influence the pathway of ATP purine signal metabolism and alleviates the gut inflammation of UC mice. Taken together, this study provides supplemental evidence to reveal the immune related mechanism of moxibustion in the treatment of UC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF